Skip to main content

Candidiasis, Oral

5
Pipeline Programs
8
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 9 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
2
MicafunginPhase 31 trial
micafunginPhase 31 trial
Active Trials
NCT00666185Completed523Est. Feb 2004
NCT00665639Completed454Est. Dec 2004
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
L-743,872Phase 2
MSD
MSDIreland - Ballydine
1 program
1
L-743,872Phase 21 trial
Active Trials
NCT00005920Terminated70
SaNOtize
SaNOtizeBC - Vancouver
1 program
1
Nitric OxidePhase 11 trial
Active Trials
NCT06120816Completed6Est. May 2024
Bristol Myers Squibb
3 programs
NystatinN/ASmall Molecule1 trial
NystatinN/ASmall Molecule1 trial
Amphotericin BPHASE_2
Active Trials
NCT00002293Completed
NCT00002057Completed
Sandoz
SandozAustria - Kundl
1 program
Terbinafine hydrochlorideN/A1 trial
Active Trials
NCT00002394Completed30
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
L-743,872PHASE_2
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Roxanes's clotrimazole trochesPHASE_31 trial
Active Trials
NCT02184351Completed187

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Astellasmicafungin
AstellasMicafungin
Boehringer IngelheimRoxanes's clotrimazole troches
SaNOtizeNitric Oxide

Clinical Trials (8)

Total enrollment: 1,270 patients across 8 trials

NCT00665639Astellasmicafungin

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

Start: Jun 2004Est. completion: Dec 2004454 patients
Phase 3Completed
NCT00666185AstellasMicafungin

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

Start: Aug 2003Est. completion: Feb 2004523 patients
Phase 3Completed
NCT02184351Boehringer IngelheimRoxanes's clotrimazole troches

Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis

Start: May 2001187 patients
Phase 3Completed
NCT00005920MSDL-743,872

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

70 patients
Phase 2Terminated
NCT06120816SaNOtizeNitric Oxide

Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis

Start: Jan 2024Est. completion: May 20246 patients
Phase 1Completed
NCT00002293Bristol Myers SquibbNystatin

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

N/ACompleted
NCT00002057Bristol Myers SquibbNystatin

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

N/ACompleted
NCT00002394SandozTerbinafine hydrochloride

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

30 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.